New MRI-Guided radiation trial aims to outsmart aggressive brain tumors

NCT ID NCT07457307

Not yet recruiting Disease control Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests whether using a special MRI-guided radiation machine (MR-Linac) can safely deliver higher, more targeted radiation doses to aggressive brain tumors (high-grade glioma). Twenty newly diagnosed patients will receive radiation twice a week for three weeks along with daily temozolomide chemotherapy. The main goal is to check for severe side effects, not yet to prove the treatment works better.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Temozolomide (chemotherapy) and MR-Linac guided radiation therapy
What this could lead to: If successful, this could point toward a more precise, safer way to deliver higher doses of radiation for glioblastoma, potentially improving tumor control.
What could go wrong: This is a very early Phase 1 safety study with only 20 participants. It is not designed to prove effectiveness, and the approach may not improve survival or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIGH GRADE GLIOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

NYU Langone Health

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.